<DOC>
	<DOCNO>NCT01895361</DOCNO>
	<brief_summary>The purpose study determine whether investigational drug SelG1 give sickle cell disease patient either take take hydroxyurea effective prevent reduce occurrence pain crisis . SelG1 prevent various cell bloodstream stick together . By stop cell-cell interaction , SelG1 may prevent small blood vessel become block therefore reduce occurrence severity pain crisis . Other effect SelG1 also evaluate , well safety drug long stay blood stream . Funding Source - FDA Office Orphan Products Development ( OOPD )</brief_summary>
	<brief_title>Study Assess Safety Impact SelG1 With Without Hydroxyurea Therapy Sickle Cell Disease Patients With Pain Crises</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Key Sickle Cell Disease ( HbSS , HbSC , HbSβ⁰thalassemia , HbSβ⁺thalassemia ) If receive hydroxyurea erythropoietin , treatment must prescribe least 6 month , dose stable least 3 month Between 2 10 sickle cellrelated pain crisis past 12 month Key On chronic transfusion program planning exchange transfusion study Hemoglobin &lt; 4.0 g/dL Planned initiation , termination , dose alteration hydroxyurea study Receiving chronic anticoagulation therapy ( e.g . warfarin , heparin ) aspirin</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>SelG1</keyword>
	<keyword>P-selectin</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>sickle cell disease</keyword>
	<keyword>sickle cell anemia</keyword>
	<keyword>sickle cell</keyword>
	<keyword>pain crisis</keyword>
	<keyword>pain crisis</keyword>
	<keyword>vasoocclusion</keyword>
	<keyword>vaso-occlusion</keyword>
	<keyword>priapism</keyword>
	<keyword>hepatic sequestration</keyword>
	<keyword>splenic sequestration</keyword>
	<keyword>chest syndrome</keyword>
</DOC>